Detalhe da pesquisa
1.
De-escalated neoadjuvant pertuzumab plus trastuzumab therapy with or without weekly paclitaxel in HER2-positive, hormone receptor-negative, early breast cancer (WSG-ADAPT-HER2+/HR-): survival outcomes from a multicentre, open-label, randomised, phase 2 trial.
Lancet Oncol
; 23(5): 625-635, 2022 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-35405088
2.
A Prospective, Multicenter Registry Study to Evaluate the Clinical Feasibility of Targeted Axillary Dissection (TAD) in Node-positive Breast Cancer Patients.
Ann Surg
; 276(5): e553-e562, 2022 11 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33156057
3.
Magnetic resonance imaging and ultrasound for prediction of residual tumor size in early breast cancer within the ADAPT subtrials.
Breast Cancer Res
; 23(1): 36, 2021 03 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-33736679
4.
Early response by MR imaging and ultrasound as predictor of pathologic complete response to 12-week neoadjuvant therapy for different early breast cancer subtypes: Combined analysis from the WSG ADAPT subtrials.
Int J Cancer
; 148(10): 2614-2627, 2021 May 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-33533487
5.
Sorafenib plus topotecan versus placebo plus topotecan for platinum-resistant ovarian cancer (TRIAS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
Lancet Oncol
; 19(9): 1247-1258, 2018 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-30100379
6.
A randomized phase 2 study comparing EC or CMF versus nab-paclitaxel plus capecitabine as adjuvant chemotherapy for nonfrail elderly patients with moderate to high-risk early breast cancer (ICE II-GBG 52).
Cancer
; 121(20): 3639-48, 2015 Oct 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-26111104
7.
Efficacy of Endocrine Therapy Plus Trastuzumab and Pertuzumab vs De-escalated Chemotherapy in Patients with Hormone Receptor-Positive/ERBB2-Positive Early Breast Cancer: The Neoadjuvant WSG-TP-II Randomized Clinical Trial.
JAMA Oncol
; 9(7): 946-954, 2023 07 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37166817
8.
De-Escalated Neoadjuvant Trastuzumab-Emtansine With or Without Endocrine Therapy Versus Trastuzumab With Endocrine Therapy in HR+/HER2+ Early Breast Cancer: 5-Year Survival in the WSG-ADAPT-TP Trial.
J Clin Oncol
; 41(22): 3796-3804, 2023 08 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36809046
9.
Impact of RNA Signatures on pCR and Survival after 12-Week Neoadjuvant Pertuzumab plus Trastuzumab with or without Paclitaxel in the WSG-ADAPT HER2+/HR- Trial.
Clin Cancer Res
; 29(4): 805-814, 2023 02 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-36441798
10.
Endocrine Therapy Response and 21-Gene Expression Assay for Therapy Guidance in HR+/HER2- Early Breast Cancer.
J Clin Oncol
; 40(23): 2557-2567, 2022 08 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-35404683
11.
The use of breast ultrasound for prediction of pathologic complete response in different subtypes of early breast cancer within the WSG-ADAPT subtrials.
Breast
; 59: 58-66, 2021 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-34166854
12.
Immune Markers and Tumor-Related Processes Predict Neoadjuvant Therapy Response in the WSG-ADAPT HER2-Positive/Hormone Receptor-Positive Trial in Early Breast Cancer.
Cancers (Basel)
; 13(19)2021 Sep 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-34638369
13.
Central Review of Radiation Therapy Planning Among Patients with Breast-Conserving Surgery: Results from a Quality Assurance Process Integrated into the INSEMA Trial.
Int J Radiat Oncol Biol Phys
; 107(4): 683-693, 2020 07 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-32437921
14.
Comparison of Neoadjuvant Nab-Paclitaxel+Carboplatin vs Nab-Paclitaxel+Gemcitabine in Triple-Negative Breast Cancer: Randomized WSG-ADAPT-TN Trial Results.
J Natl Cancer Inst
; 110(6): 628-637, 2018 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29228315
15.
De-Escalation Strategies in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer (BC): Final Analysis of the West German Study Group Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early BC HER2- and Hormone Receptor-Positive Phase II Randomized Trial-Efficacy, Safety, and Predictive Markers for 12 Weeks of Neoadjuvant Trastuzumab Emtansine With or Without Endocrine Therapy (ET) Versus Trastuzumab Plus ET.
J Clin Oncol
; 35(26): 3046-3054, 2017 Sep 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-28682681
16.
Mapisal Versus Urea Cream as Prophylaxis for Capecitabine-Associated Hand-Foot Syndrome: A Randomized Phase III Trial of the AIO Quality of Life Working Group.
J Clin Oncol
; 33(22): 2444-9, 2015 Aug 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-26124485